1. Home
  2. |Insights
  3. |DEAL NOTE: Crowell & Moring Advises Humana Inc. on Acquisition of Enclara Healthcare

DEAL NOTE: Crowell & Moring Advises Humana Inc. on Acquisition of Enclara Healthcare

Firm News | 1 min read | 12.16.19

Washington – December 16, 2019: Crowell & Moring advised Humana Inc. on its proposed acquisition of Enclara Healthcare, one of the nation’s largest hospice pharmacy and benefit management providers, from Consonance Capital Partners. The Enclara acquisition provides Humana with the opportunity to extend its comprehensive care continuum strategy to cover the pharmacy-related needs associated with hospice care, simplify the mail order pharmacy experience, and advance its technology stack for in-home pharmacy through areas such as enhanced mobile medication management and improved electronic medical record (EMR) connectivity.

The transaction will include the acquisition of Enclara Pharmacia, Guidant Rx and Avanti Health Care Services and is expected to close in the first half of 2020 after going through the customary regulatory approvals at state and federal levels.

Crowell & Moring served as legal counsel for Humana using a cross-practice team to support the acquisition, including members of the corporate, health care, and tax practices. Partners involved in the transaction were Paul Pollock, Stephanie Marcantonio, Troy Barsky, Charlie Hwang, David McFarlane, Shawn Johnson, Evan Wolff, and Scott Moore.

About Crowell & Moring LLP

Crowell & Moring LLP is an international law firm with more than 550 lawyers representing clients in litigation and arbitration, regulatory, and transactional matters. The firm is internationally recognized for its representation of Fortune 500 companies in high-stakes litigation, as well as its ongoing commitment to pro bono service and diversity. The firm has offices in Washington, D.C., New York, Los Angeles, San Francisco, Orange County, London, and Brussels.

Insights

Firm News | 1 min read | 03.11.25

Crowell & Moring Represents Nuclear Energy Startup Atomic Alchemy in its Acquisition by Oklo

March 11, 2025: Oklo Inc. (NYSE: OKLO), an advanced nuclear technology company, announced on March 5, 2025 that it has closed the $25 million acquisition of Crowell client Atomic Alchemy Inc. (“Atomic Alchemy”), a leading innovator in radioisotope production. Oklo intends to use this strategic acquisition to establish a more reliable domestic supply chain for high-value radioisotopes critical to healthcare, research, and defense sectors and provides synergies to Oklo’s fuel recycling and nuclear energy businesses. Demand for radioisotopes is expected to increase significantly over the next decade, while global supply struggles to keep pace due to aging reactor infrastructure and a fragmented global supply chain, which at present is dominated by countries outside the United States. Atomic Alchemy intends to be a low-cost U.S. radioisotope producer that can provide a secure and domestic supply of radioisotopes to U.S. companies commercializing innovative radioisotope applications. With its proprietary VIPR® technology, Atomic Alchemy is building the first scalable production facility to provide a reliable, sustainable source of high-value radioisotopes. Using a vertically integrated model and fuel recycling, in partnership with Oklo, Atomic Alchemy is transforming isotope production to address global shortages, support critical applications, and strengthen national security. The core deal team included Samuel Holland Edwards, Jon O’Connell, Justin Lurie, and Ryan Flynn....

View All Insights